⌕
Collegium Pharmaceutical · COLL · Nasdaq
Tenet 60 · Solid
Compare
$25.55+0.47%At closeTenet 60 · Solid
$25.55+0.12 (+0.47%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Collegium Pharmaceutical (COLL) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~29.6%/yr (FY21→FY25), net margin 8.1%, and free cash flow (~$327.6M) tracks net income. Earnings are cash, not paper.
The four lines that matter · FY21–FY25
Revenue ($M)▲23.6%
780.6
FY21→FY25CAGR +29.6%/yr
Net income ($M)▼9.1%
62.9
one-off year: see footnoteCAGR −3.2%/yr
Free cash flow ($M)▲61.1%
327.6
FY21→FY25CAGR +34.0%/yr
Diluted EPS▼7.0%
1.73
buyback-liftedCAGR −1.8%/yr
What the receipts whisper · what a headline number hides
Share count
−3.3%

41.0mn → 39.7mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.

Capex
$1.7M

steady at 0.2% of revenue (+5.3% YoY).

Returns vs FCF
8%

$25.1M returned vs $327.6M of FCF in FY25. Buybacks covered by cash flow.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)780.6Revenue−317.3COGS463.3Gross profit−284.8SG&A179.6Op income−116.8Tax & other62.9Net income

8¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.

Margin trend · direction beats level Gross Operating Net
604530150%sector median net margin ~3%FY21FY25

Over this window: gross 54.4% → 59.3%. Net margin 8.1% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
815.2780.6631.4566.8463.9276.9▲23.6%+29.6%
Cost of revenue
333.9317.3254.1240.6254.4126.3▲24.9%+25.9%
Gross profit
481.3463.3377.3326.2209.5150.6▲22.8%+32.4%
Research & development
————4.09.5——
Selling, general & admin
360.2284.8210.4159.2172.2119.0▲35.4%+24.4%
Total operating expenses
357.3283.6207.4159.2176.2133.0▲36.7%+20.8%
Operating incomefeeds ROC rank
124.1179.6169.9167.033.317.6▲5.7%+78.7%
Other income, net
−81.9−87.0−71.3−91.2−62.2−21.0——
Pretax income
42.192.698.675.7−28.8−3.4▼6.0%—
Income tax
4.029.729.427.6−3.8−74.9▲1.3%—
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
38.262.969.248.2−25.071.5▼9.1%−3.2%
Per share
Diluted EPSbuyback-sensitive
1.021.731.861.29−0.741.86▼7.0%−1.8%
Diluted shares (mn)
39.1139.7040.4241.7933.8341.05▼1.8%−0.8%
Margins
Gross margin40th pct in Healthcare
59.0%59.3%59.8%57.5%45.2%54.4%▼0.4pp+4.9pp
Operating margin
15.2%23.0%26.9%29.5%7.2%6.4%▼3.9pp+16.6pp
Net margin55th pct in Healthcare
4.7%8.1%11.0%8.5%−5.4%25.8%▼2.9pp−17.8pp
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was 2220% vs a 32% norm for this window, likely a one-time item; see the filing.FY22 effective tax rate was 13% vs a 32% norm for this window, likely a one-time item; see the filing.
FY13 – FY20 · 8 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 8 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Collegium Pharmaceutical's revenue last fiscal year?

Collegium Pharmaceutical reported revenue of $780.6M in fiscal 2025, up 23.6% from fiscal 2024.

What was Collegium Pharmaceutical's net income?

Collegium Pharmaceutical reported net income of $62.9M in fiscal 2025, a net margin of 8.1%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.